Immunic Historical Financial Ratios

IMUX Stock  USD 1.13  0.08  6.61%   
Immunic is lately reporting on over 113 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as PTB Ratio of 1.46 or Days Sales Outstanding of 0.0 will help investors to properly organize and evaluate Immunic financial condition quickly.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunic. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
For more information on how to buy Immunic Stock please use our How to Invest in Immunic guide.

About Immunic Financial Ratios Analysis

ImmunicFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Immunic investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Immunic financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Immunic history.

Immunic Financial Ratios Chart

At this time, Immunic's Book Value Per Share is fairly stable compared to the past year. Capex To Depreciation is likely to rise to 3.16 in 2024, whereas PTB Ratio is likely to drop 1.46 in 2024.
Add Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Price Book Value RatioPrice Earnings To Growth Ratio
Days Of Payables OutstandingDividend Payout Ratio
Price To Operating Cash Flows RatioPrice To Free Cash Flows Ratio
Pretax Profit MarginEbt Per Ebit
Operating Profit MarginEffective Tax Rate
Company Equity MultiplierLong Term Debt To Capitalization
Total Debt To CapitalizationReturn On Capital Employed
Debt Equity RatioEbit Per Revenue
Quick RatioDividend Paid And Capex Coverage Ratio
Net Income Per E B TCash Ratio
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On EquityOperating Cycle
Cash Conversion Cycle

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Immunic stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Immunic sales, a figure that is much harder to manipulate than other Immunic multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Dividend Yield

Dividend Yield is Immunic dividend as a percentage of Immunic stock price. Immunic dividend yield is a measure of Immunic stock productivity, which can be interpreted as interest rate earned on an Immunic investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.

Ptb Ratio

Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.

Asset Turnover

The ratio of net sales to average total assets, indicating how efficiently a company uses its assets to generate sales.
Most ratios from Immunic's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Immunic current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunic. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
For more information on how to buy Immunic Stock please use our How to Invest in Immunic guide.At this time, Immunic's Book Value Per Share is fairly stable compared to the past year. Capex To Depreciation is likely to rise to 3.16 in 2024, whereas PTB Ratio is likely to drop 1.46 in 2024.
 2010 2023 2024 (projected)
Dividend Yield0.0079850.0071870.006388
Price To Sales Ratio21.6K19.5K17.3K

Immunic fundamentals Correlations

1.0-0.01-0.08-0.04-0.19-0.58-0.011.0-0.190.64-0.41-0.170.350.351.00.16-0.21-0.18-0.8-0.23-0.21-0.140.060.64-0.2
1.0-0.01-0.08-0.04-0.19-0.58-0.011.0-0.190.64-0.41-0.170.350.351.00.16-0.21-0.18-0.8-0.23-0.21-0.140.060.64-0.2
-0.01-0.010.270.470.430.161.0-0.010.42-0.18-0.040.350.00.15-0.01-0.32-0.87-0.590.07-0.28-0.87-0.12-0.48-0.13-0.86
-0.08-0.080.27-0.26-0.210.460.27-0.08-0.23-0.350.1-0.340.01-0.13-0.080.49-0.14-0.650.08-0.53-0.140.16-0.63-0.31-0.04
-0.04-0.040.47-0.260.520.060.47-0.040.520.360.130.540.150.15-0.04-0.5-0.510.160.040.24-0.510.17-0.10.4-0.45
-0.19-0.190.43-0.210.520.130.43-0.191.0-0.320.260.990.02-0.33-0.19-0.93-0.31-0.020.190.55-0.310.4-0.27-0.31-0.32
-0.58-0.580.160.460.060.130.16-0.580.12-0.50.710.050.32-0.54-0.58-0.01-0.06-0.030.570.01-0.070.65-0.33-0.470.05
-0.01-0.011.00.270.470.430.16-0.010.42-0.18-0.040.350.00.15-0.01-0.32-0.87-0.590.07-0.28-0.87-0.12-0.48-0.13-0.86
1.01.0-0.01-0.08-0.04-0.19-0.58-0.01-0.190.64-0.41-0.170.350.351.00.16-0.21-0.18-0.8-0.23-0.21-0.140.060.64-0.2
-0.19-0.190.42-0.230.521.00.120.42-0.19-0.320.250.990.02-0.32-0.19-0.93-0.30.00.190.56-0.310.39-0.25-0.3-0.32
0.640.64-0.18-0.350.36-0.32-0.5-0.180.64-0.32-0.32-0.230.340.510.640.27-0.180.29-0.66-0.19-0.18-0.250.481.0-0.15
-0.41-0.41-0.040.10.130.260.71-0.04-0.410.25-0.320.220.31-0.47-0.41-0.210.080.440.420.350.070.68-0.17-0.310.18
-0.17-0.170.35-0.340.540.990.050.35-0.170.99-0.230.220.02-0.29-0.17-0.94-0.270.10.170.59-0.270.35-0.14-0.22-0.3
0.350.350.00.010.150.020.320.00.350.020.340.310.02-0.050.35-0.02-0.240.03-0.360.04-0.250.470.230.37-0.15
0.350.350.15-0.130.15-0.33-0.540.150.35-0.320.51-0.47-0.29-0.050.350.28-0.25-0.21-0.36-0.49-0.25-0.750.270.51-0.26
1.01.0-0.01-0.08-0.04-0.19-0.58-0.011.0-0.190.64-0.41-0.170.350.350.16-0.21-0.18-0.8-0.23-0.21-0.140.060.64-0.2
0.160.16-0.320.49-0.5-0.93-0.01-0.320.16-0.930.27-0.21-0.94-0.020.280.160.22-0.13-0.16-0.680.22-0.330.120.260.26
-0.21-0.21-0.87-0.14-0.51-0.31-0.06-0.87-0.21-0.3-0.180.08-0.27-0.24-0.25-0.210.220.440.220.331.00.110.23-0.230.98
-0.18-0.18-0.59-0.650.16-0.02-0.03-0.59-0.180.00.290.440.10.03-0.21-0.18-0.130.440.190.530.430.220.540.250.42
-0.8-0.80.070.080.040.190.570.07-0.80.19-0.660.420.17-0.36-0.36-0.8-0.160.220.190.240.220.22-0.19-0.670.2
-0.23-0.23-0.28-0.530.240.550.01-0.28-0.230.56-0.190.350.590.04-0.49-0.23-0.680.330.530.240.320.560.01-0.20.31
-0.21-0.21-0.87-0.14-0.51-0.31-0.07-0.87-0.21-0.31-0.180.07-0.27-0.25-0.25-0.210.221.00.430.220.320.10.23-0.230.98
-0.14-0.14-0.120.160.170.40.65-0.12-0.140.39-0.250.680.350.47-0.75-0.14-0.330.110.220.220.560.1-0.34-0.220.22
0.060.06-0.48-0.63-0.1-0.27-0.33-0.480.06-0.250.48-0.17-0.140.230.270.060.120.230.54-0.190.010.23-0.340.440.13
0.640.64-0.13-0.310.4-0.31-0.47-0.130.64-0.31.0-0.31-0.220.370.510.640.26-0.230.25-0.67-0.2-0.23-0.220.44-0.19
-0.2-0.2-0.86-0.04-0.45-0.320.05-0.86-0.2-0.32-0.150.18-0.3-0.15-0.26-0.20.260.980.420.20.310.980.220.13-0.19
Click cells to compare fundamentals

Immunic Account Relationship Matchups

Immunic fundamentals Accounts

201920202021202220232024 (projected)
Ptb Ratio1.281.511.780.392.31.46
Book Value Per Share7.5610.145.373.570.650.69
Free Cash Flow Yield(0.38)(0.19)(0.37)(1.46)(1.07)(1.12)
Operating Cash Flow Per Share(3.7)(2.94)(3.52)(2.05)(1.6)(1.68)
Capex To Depreciation1.13.740.791.453.013.16
Pb Ratio1.281.511.780.392.31.46
Free Cash Flow Per Share(3.7)(2.95)(3.52)(2.05)(1.61)(1.69)
Roic(3.43)(0.63)(0.31)(0.72)(1.35)(3.26)
Inventory Turnover(0.12)0.0114(0.0395)(0.029)(0.0261)(0.0274)
Net Income Per Share(4.51)(2.81)(3.92)(4.85)(2.11)(2.22)
Days Of Inventory On Hand(3.0K)32.0K(9.2K)(12.6K)(14.5K)(13.8K)
Payables Turnover0.02060.01050.02270.0180.02180.0207
Cash Per Share3.88.143.673.661.051.0
Pocfratio(2.62)(5.19)(2.72)(0.68)(0.94)(0.99)
Capex To Operating Cash Flow(0.001927)(0.003165)(8.05E-4)(0.001719)(0.004716)(0.004951)
Pfcf Ratio(2.62)(5.18)(2.72)(0.68)(0.93)(0.98)
Days Payables Outstanding17.7K34.6K16.1K20.3K16.8K10.0K
Income Quality0.821.050.90.540.761.02
Roe(0.6)(0.28)(0.73)(1.36)(3.24)(3.07)
Ev To Operating Cash Flow(1.61)(2.44)(1.68)0.93(0.3)(0.31)
Pe Ratio(2.15)(5.45)(2.44)(0.29)(0.71)(0.75)
Ev To Free Cash Flow(1.61)(2.44)(1.68)0.93(0.3)(0.31)
Net Debt To E B I T D A0.782.590.930.870.460.43
Current Ratio4.5615.939.219.622.122.02
Tangible Book Value Per Share3.298.033.983.570.650.69
Graham Number27.6925.321.7819.745.575.29
Shareholders Equity Per Share7.5610.145.373.570.650.69
Capex Per Share0.0071220.0093210.0028330.003520.0075360.007159
Graham Net Net2.797.673.123.170.480.5
Enterprise Value Over E B I T D A(1.25)(2.3)(1.51)0.5(0.21)(0.22)
Price Earnings Ratio(2.15)(5.45)(2.44)(0.29)(0.71)(0.75)
Price Book Value Ratio1.281.511.780.392.31.46
Price Earnings To Growth Ratio0.02430.14(0.0618)(0.0122)0.01260.0132
Days Of Payables Outstanding17.7K34.6K16.1K20.3K16.8K10.0K
Price To Operating Cash Flows Ratio(2.62)(5.19)(2.72)(0.68)(0.94)(0.99)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Immunic Stock Analysis

When running Immunic's price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.